WEREWOLF THERAPEUTICS, INC. Increase (Decrease) in Accrued Liabilities
WEREWOLF THERAPEUTICS, INC. (HOWL) reported Increase (Decrease) in Accrued Liabilities of -$5.34 million for the 9-month period ending 2023-09-30, per its 10-Q filed 2023-11-14.
Discontinued › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccruedLiabilities · last filed 2023-11-14
- WEREWOLF THERAPEUTICS, INC. increase (decrease) in accrued liabilities for the quarter ending 2023-09-30 was -$2.17M, a 288.60% decline year-over-year.
- WEREWOLF THERAPEUTICS, INC. increase (decrease) in accrued liabilities for the quarter ending 2023-06-30 was -$3.30M, a 159.44% decline year-over-year.
- WEREWOLF THERAPEUTICS, INC. increase (decrease) in accrued liabilities for the quarter ending 2023-03-31 was $133.00K.
- WEREWOLF THERAPEUTICS, INC. increase (decrease) in accrued liabilities for the quarter ending 2022-12-31 was -$939.00K, a 130.09% decline year-over-year.
- WEREWOLF THERAPEUTICS, INC. increase (decrease) in accrued liabilities for fiscal 2022 was $3.74M, a 28.98% decline from fiscal 2021.
- WEREWOLF THERAPEUTICS, INC. increase (decrease) in accrued liabilities for fiscal 2021 was $5.26M, a 101.19% increase from fiscal 2020.
- WEREWOLF THERAPEUTICS, INC. increase (decrease) in accrued liabilities for fiscal 2020 was $2.62M.
| Period end | Increase (Decrease) in Accrued Liabilities 3 month | Increase (Decrease) in Accrued Liabilities 6 month | Increase (Decrease) in Accrued Liabilities 9 month | Increase (Decrease) in Accrued Liabilities 12 month |
|---|---|---|---|---|
| 2023-09-30 | -$2.17M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-14 | -$5.47M derived: sum of 2 quarters · filed 2023-11-14 | -$5.34M 10-Q · filed 2023-11-14 | -$6.28M derived: sum of 4 quarters · filed 2023-11-14 |
| 2023-06-30 | -$3.30M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-10 | -$3.17M 10-Q · filed 2023-08-10 | -$4.11M derived: sum of 3 quarters · filed 2023-08-10 | -$2.96M derived: sum of 4 quarters · filed 2023-11-14 |
| 2023-03-31 | $133.00K 10-Q · filed 2023-05-11 | -$806.00K derived: sum of 2 quarters · filed 2023-05-11 | $343.00K derived: sum of 3 quarters · filed 2023-11-14 | $5.90M derived: sum of 4 quarters · filed 2023-11-14 |
| 2022-12-31 | -$939.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-23 | $210.00K derived: sum of 2 quarters · filed 2023-11-14 | $5.77M derived: sum of 3 quarters · filed 2023-11-14 | $3.74M 10-K · filed 2023-03-23 |
| 2022-09-30 | $1.15M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-14 | $6.71M derived: sum of 2 quarters · filed 2023-11-14 | $4.68M 10-Q · filed 2023-11-14 | $7.80M derived: sum of 4 quarters · filed 2023-11-14 |
| 2022-06-30 | $5.56M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-10 | $3.53M 10-Q · filed 2023-08-10 | $6.65M derived: sum of 3 quarters · filed 2023-08-10 | $8.79M derived: sum of 4 quarters · filed 2023-08-10 |
| 2022-03-31 | -$2.03M 10-Q · filed 2023-05-11 | $1.09M derived: sum of 2 quarters · filed 2023-05-11 | $3.23M derived: sum of 3 quarters · filed 2023-05-11 | $4.56M derived: sum of 4 quarters · filed 2023-05-11 |
| 2021-12-31 | $3.12M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-23 | $5.26M derived: sum of 2 quarters · filed 2023-03-23 | $6.59M derived: sum of 3 quarters · filed 2023-03-23 | $5.26M 10-K · filed 2023-03-23 |
| 2021-09-30 | $2.14M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-10 | $3.47M derived: sum of 2 quarters · filed 2022-11-10 | $2.14M 10-Q · filed 2022-11-10 | $3.96M derived: sum of 4 quarters · filed 2022-11-10 |
| 2021-06-30 | $1.33M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-11 | -$1.00K 10-Q · filed 2022-08-11 | $1.82M derived: sum of 3 quarters · filed 2022-08-11 | $2.49M derived: sum of 4 quarters · filed 2022-08-11 |
| 2021-03-31 | -$1.33M 10-Q · filed 2022-05-10 | $492.00K derived: sum of 2 quarters · filed 2022-05-10 | $1.16M derived: sum of 3 quarters · filed 2022-05-10 | $1.33M derived: sum of 4 quarters · filed 2022-05-10 |
| 2020-12-31 | $1.82M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-24 | $2.49M derived: sum of 2 quarters · filed 2022-03-24 | $2.66M derived: sum of 3 quarters · filed 2022-03-24 | $2.62M 10-K · filed 2022-03-24 |
| 2020-09-30 | $665.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-10 | $840.00K derived: sum of 2 quarters · filed 2021-11-10 | $793.00K 10-Q · filed 2021-11-10 | |
| 2020-06-30 | $175.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-12 | $128.00K 10-Q · filed 2021-08-12 | ||
| 2020-03-31 | -$47.00K 10-Q · filed 2021-06-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Grace Therapeutics, Inc. (GRCE) | $0.046B | -1.83 | |
| Dogwood Therapeutics, Inc. (DWTX) | United States | $0.049B | |
| Lite Strategy, Inc. (LITS) | United States | $0.049B | |
| Elicio Therapeutics, Inc. (ELTX) | United States | $0.049B | |
| PDS Biotechnology Corp (PDSB) | United States | $0.045B | |
| SCYNEXIS INC (SCYX) | United States | $0.045B | |
| VERU INC. (VERU) | United States | $0.043B | -3.93 |
| Xilio Therapeutics, Inc. (XLO) | United States | $0.052B | |
| Kairos Pharma, LTD. (KAPA) | United States | $0.041B | |
| Incannex Healthcare Inc. (IXHL) | $0.040B | -22.32 |